Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2019-10-08 Director's Dealing
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-10-08 English
FORM 4
Director's Dealing
2019-10-08 English
FORM 4
Director's Dealing
2019-10-08 English
FORM 4
Director's Dealing
2019-10-08 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 7, 2019, by Aprea Therapeutics, Inc. It reports amendments to the Articles of Incorporation and Bylaws in connection with the company's initial public offering. The document includes descriptions of the Restated Certificate of Incorporation and Restated Bylaws, referencing exhibits filed with the report. There are no financial statements or detailed financial data included, nor is this a report of earnings, management discussion, or other financial disclosures. The content focuses on corporate governance changes and filings related to corporate structure amendments. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related corporate governance documents. The document is not a full annual or quarterly report, nor an earnings release or proxy statement. Therefore, the appropriate classification is MANG with high confidence.
2019-10-07 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(4) related to an initial public offering (IPO) of common stock by Aprea Therapeutics, Inc. It includes detailed information about the offering, underwriting, risk factors, financial data, corporate reorganization, and other disclosures typical of a registration statement prospectus. The presence of the term 'prospectus' and the detailed offering information indicates this is a capital markets filing related to a securities offering. It is not an annual report, earnings release, or management discussion. It is not a report publication announcement or a regulatory filing in the fallback sense, but a primary offering document. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-10-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.